Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 3, 2016

M&As this week: Signal Genetics, Celldex Therapeutics

US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies having unanimously approved the merger that will create a clinical-stage biopharmaceutical company.

US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies having unanimously approved the merger that will create a clinical-stage biopharmaceutical company.

Mirage’s shareholders will hold roughly 96% of Signal’s outstanding common stock on a fully diluted basis and Signal’s name will be changed to MiRagen, Inc.

"The merged company is expected to have a cash balance of $50m and will focus on developing proprietary micro RNA-targeted therapeutics."

The merged company is expected to have a cash balance of $50m and will focus on developing proprietary micro RNA-targeted therapeutics.

Connemara Merger Sub 1 and Connemara Merger Sub 2, the subsidiaries of US-based biopharmaceutical company Celldex Therapeutics, have signed an agreement to acquire Kolltan Pharmaceuticals in a stock-for-stock transaction.

Following the acquisition, which is estimated to cost up to $235m, clinical-stage biopharmaceutical company Kolltan Pharmaceuticals will become a wholly owned subsidiary of Celldex Therapeutics.

Celldex Therapeutics aims to expand its antibody and immuno-oncology portfolio through the acquisition.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU